Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

VEXAS (acronym for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a
fascinating new entity encompassing a variety of clinical manifestations, spanning from auto …

Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)
T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell …

Cancer cells edit gene expression to evade immunosurveillance. However, genome-wide
studies of gene editing during early tumorigenesis are lacking. Here we used single-cell …

Major efforts are underway to identify agents that can potentiate effects of immune
checkpoint inhibition. Here, we show that ascorbic acid (AA) treatment caused genomewide …

Decitabine is a hypomethylating agent that irreversibly inhibits DNA methyltransferase I,
inducing leukemic differentiation and re-expression of epigenetically silenced putative tumor …

Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) has revolutionized the
field of cancer treatment; however, ICI efficacy is constrained by progressive dysfunction of …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic
landscape of haematological malignancies. However, resistance and relapse remain …

Epigenetic alterations are strongly associated with cancer development and drug resistance.
The use of the DNA methylation inhibitor decitabine (Dacogen®) has been approved in the …

The recognition of the curative potential of the graft‐versus‐leukaemia effect for patients with
acute myeloid leukaemia (AML) undergoing stem cell transplantation, and the emergence of …